MARINUS PHARMACEUTICALS INC (MRNS)
US56854Q2003 - Common Stock
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024
Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference
Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q2 2024
MRNS stock results show that Marinus Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Marinus Pharma (NASDAQ:MRNS) just reported results for the second quarter of 20...
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
3 Biotech Stocks to Sell in August Before They Crash & Burn
Investors should keep a watchful eye out for these three biotech stocks to sell before a potential dip damages their gains.
MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
Marinus Pharmaceuticals, Inc. Class Action: The Gross Law Firm Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 - MRNS
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS). Shareholders who purchased...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit Filed by Rosen Law Firm
/PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS)...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)
MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus
Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRNS
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) of a class action...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNS
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ:...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Marinus To Contact Him...
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024
Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) of a class action...
